Spots Global Cancer Trial Database for Study of the AL3810 in the Treatment of Advanced Solid Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of the AL3810 in the Treatment of Advanced Solid Tumor
Official Title: An Open-label, Dose-finding Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, Pharmacodynamics of the Dual -VEGFR-FGFR Tyrosine Kinase Inhibitor, AL3810, Givenorally as Single Agent to Patients With Advanced Solid Tumours
Study ID: NCT03117101
Conditions
Interventions
Study Description
Brief Summary: This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study
Detailed Description: Methodology: This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study with a traditional 3+3 design, conducted in Chinese patients with advanced solid tumours without an established therapeutic alternative.This study was performed in strict accordance with Good Clinical Practice including the archiving of essential documents.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Contact Details
Name: Jin Li, M.D.
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Name: Junning Cao, M.D.
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
